Who are Clindamycin and BPO 5% gel's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clindamycin-and-bpo-5-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Clindamycin and BPO 5% gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clindamycin and BPO 5% gel (Clindamycin and BPO 5% gel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic combination with keratolytic agent. Area: Dermatology.

marketed Topical antibiotic combination with keratolytic agent Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Clindamycin and BPO 5% gel (Clindamycin and BPO 5% gel) — Stiefel, a GSK Company. Clindamycin kills acne-causing bacteria while benzoyl peroxide oxidizes and destroys bacterial cell membranes and reduces sebum production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clindamycin and BPO 5% gel TARGET	Clindamycin and BPO 5% gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination with keratolytic agent	Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic combination with keratolytic agent class)

Stiefel, a GSK Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clindamycin and BPO 5% gel — Competitive Intelligence Brief. https://druglandscape.com/ci/clindamycin-and-bpo-5-gel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab